Mesenchymal Stem Cell Selection via Gene Expression Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing mesenchymal stem cell populations for intravenous administration face challenges in achieving stable quality and low cell aggregability, which is crucial for safety and efficacy, as existing techniques do not effectively select for mesenchymal stem cells with low aggregability using specific gene expression indices.
Innovation Solution
A method involving the treatment of a fetal appendage extracellular matrix layer with an enzyme solution to release mesenchymal stem cells, followed by identification of cell populations with relative expression levels of COL11A1 and COL16A1 genes to SDHA genes within specific thresholds, ensuring low cell aggregability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are collected from fetal appendages using conventional methods, then a cell population can be obtained, but the cell population has heterogeneous quality and high cell aggregability which compromises safety for intravenous administration
Solution Approach 1:
The patent applies parameter changes by establishing specific gene expression thresholds (COL11A1/SDHA ≤ 6.0 and COL16A1/SDHA ≤ 1.5) to identify and select mesenchymal stem cells with low aggregability. By measuring and filtering cells based on these quantitative gene expression parameters, the method transforms a heterogeneous cell population into a homogeneous population suitable for intravenous administration, resolving the contradiction between obtaining a cell population and ensuring its safety and homogeneity.
2Manufacturing precision
If conventional cell collection methods are used without gene expression screening, then cell production is simpler and faster, but the cell population cannot be selectively prepared with low cell aggregability
Solution Approach 1:
The patent replaces mechanical/manual cell selection methods with a molecular biology-based detection system. By using gene expression analysis (measuring COL11A1, COL16A1, and SDHA mRNA levels) to identify cells with low aggregability, the invention substitutes physical separation techniques with a precise molecular fingerprinting approach, enabling selective preparation of desired cell populations while maintaining procedural efficiency.
3Productivity
If cell aggregates form during intravenous administration, then cell therapy efficacy is reduced, but preventing aggregation requires complex selection and preparation protocols
Solution Approach 1:
The patent applies preliminary action by performing gene expression screening and cell selection before intravenous administration. By measuring COL11A1/SDHA and COL16A1/SDHA ratios in advance and selecting cells that meet the specified thresholds, the method pre-prevents cell aggregation issues that would otherwise occur during administration. This upfront selection ensures therapeutic efficacy without requiring complex intervention protocols during the actual treatment process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of a mesenchymal stem cell population with reduced cell aggregability, enhancing the safety and efficiency of intravenous administration by using gene expression ratios as indices for cell preparation.
Implementation Method 1
treating a sample comprising an extracellular matrix layer collected from a fetal appendage with an enzyme solution to release the mesenchymal stem cells contained in the extracellular matrix layer
Data Source
Figure 1
Figure 2
AI summary
An object of the present invention is to provide a cell population comprising mesenchymal cells having low cell aggregability, which is useful for intravenous administration of a cell preparation, and a method for producing the same, and a pharmaceutical composition comprising the cell population. The present invention provides a method for producing a cell population comprising mesenchymal stem cells, the method comprising obtaining a cell population having the following cell characteristics (the cell population satisfies the relative expression level of COL11A1 gene to the expression level of SDHA gene of 6.0 or less and the relative expression level of COL16A1 gene to the expression level of SDHA gene of 1.5 or less).